Impact of duration of treatments with metformin and sulfonylureas, individually or in combination, on diabetic retinopathy among newly diagnosed type 2 diabetic patients: a pooled cohort’s analysis

Table 2 The hazard ratio of the duration of using metformin and sulfonylurea on diabetic retinopathy

Model	Exposure (Medication time in years)	Cox model			Fine-Gray model
Model	Exposure (Medication time in years)	Hazard ratio	95% CI	P value	SHR	95% CI	p-value
Diabetic Retinopathy
1	Metformin	0.87	0.81,0.94	0.001	0.90	0.84,0.97	0.001
	Sulfonylurea	0.90	0.82,0.99	0.022	0.93	0.84,1.02	0.08
	Sulfonylurea + Metformin	0.86	0.79,0.94	0.001	0.90	0.82,0.99	0.006
2	Metformin	0.88	0.80,0.96	0.001	0.92	0.86,0.98	0.012
	Sulfonylurea	0.91	0.85,0.98	0.025	0.94	0.88,1.02	0.12
	Sulfonylurea + Metformin	0.87	0.79,0.96	0.001	0.91	0.86,0.97	0.001
3	Metformin	0.90	0.82,0.98	0.011	0.93	0.87,0.99	0.015
	Sulfonylurea	0.93	0.87,0.99	0.034	0.94	0.87,1.00	0.038
	Sulfonylurea + Metformin	0.89	0.80,0.98	0.001	0.91	0.84,0.99	0.001

∗ Model 1: Crude
∗ Model 2: Adjusted for Mean of age and Mean of FBS at follow-up
∗ Model 3: Adjusted for Mean of age, FBS, BMI, statin, and smoking during the follow-up period
*The CPH model was used in models 1, 2, and 3
*Fine-Gray model was used to estimate the competing risk effect

ISSN: 2056-9920